Your browser doesn't support javascript.
loading
Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer.
Puranik, Ameya D; Dromain, Clarisse; Fleshner, Neil; Sathekge, Mike; Pavel, Marianne; Eberhardt, Nina; Zengerling, Friedemann; Marienfeld, Ralf; Grunert, Michael; Prasad, Vikas.
Afiliação
  • Puranik AD; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400012, India.
  • Dromain C; Department of Diagnostic and Interventional Radiology, CHUV University Hospital, Rue du Bugnon 46, 1011 Lausanne, Switzerland.
  • Fleshner N; Department of Urology, University of Toronto, 610 University Avenue Toronto, Toronto, ON M5G 2M9, Canada.
  • Sathekge M; Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria 0001, South Africa.
  • Pavel M; Department of Medicine, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.
  • Eberhardt N; Department of Nuclear Medicine, University Hospital Ulm, 89081 Ulm, Germany.
  • Zengerling F; Department of Urology, University Hospital Ulm, 89081 Ulm, Germany.
  • Marienfeld R; Institute of Pathology, University Hospital Ulm, 89081 Ulm, Germany.
  • Grunert M; Department of Nuclear Medicine, University Hospital Ulm, 89081 Ulm, Germany.
  • Prasad V; Department of Nuclear Medicine, German Armed Forces Hospital of Ulm, 89081 Ulm, Germany.
Cancers (Basel) ; 13(14)2021 Jul 19.
Article em En | MEDLINE | ID: mdl-34298822

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article